Posted by Michael Wonder on 25 Jun 2025
Quoin Pharmaceuticals announces FDA grants rare paediatric disease designation for QRX003 in Netherton syndrome
24 June 2025 - Quoin Pharmaceuticals today announced that the US FDA has granted rare paediatric disease designation for the Company’s lead asset, QRX003, for the treatment of Netherton syndrome.
The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved paediatric population. It follows earlier regulatory recognition by the EMA, which granted orphan drug designation to QRX003 in May 2025.
